Statements (71)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Opko_Health
|
| gptkbp:advertising |
global market access
focus on innovative therapies |
| gptkbp:businessModel |
biotechnology development
targeted through innovation |
| gptkbp:CEO |
gptkb:Dr._Phillip_Frost
|
| gptkbp:challenges |
addressed through R&D
|
| gptkbp:clinicalTrials |
endocrinology
completed successfully conducted in multiple countries growth hormone deficiency hGH-CTP Phase 3 positive results for hGH-CTP |
| gptkbp:collaborations |
academic institutions
with universities |
| gptkbp:community_engagement |
involved in local initiatives
|
| gptkbp:community_service |
defined for trials
|
| gptkbp:competitors |
conducted for product development
monitored for strategic planning |
| gptkbp:culturalHeritage |
innovation-driven
|
| gptkbp:employeeCount |
approximately 50
|
| gptkbp:feedback |
monitored during trials
|
| gptkbp:financialPerformance |
publicly traded
|
| gptkbp:financials |
held regularly
focused on R&D |
| gptkbp:focus |
development of long-acting therapeutics
|
| gptkbp:founded |
2008
|
| gptkbp:founder |
gptkb:Dr._David_S._Kessler
|
| gptkbp:funding |
secured from investors
|
| gptkbp:future_plans |
expand product line
|
| gptkbp:headquarters |
gptkb:Rehovot,_Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prolor Biotech
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:investmentFocus |
gptkb:Opko_Health
venture capital firms |
| gptkbp:is_a |
public company
|
| gptkbp:is_part_of |
Opko_Health_portfolio
|
| gptkbp:keyIssues |
CTP technology
|
| gptkbp:leadership |
experienced management team
|
| gptkbp:location |
gptkb:Israel
|
| gptkbp:market |
international
strategically planned. growth hormone deficiency |
| gptkbp:notableEvent |
hGH-CTP
|
| gptkbp:parent_company |
improve patient outcomes
|
| gptkbp:partnerships |
gptkb:Opko_Health
strategic alliances with pharmaceutical companies |
| gptkbp:patentCitation |
multiple patents in biotechnology
|
| gptkbp:productLine |
hGH-CTP
|
| gptkbp:products |
ongoing
biopharmaceuticals demonstrated in studies adapted to market needs long-acting formulations |
| gptkbp:regulatoryCompliance |
submitted to health authorities
ensured through quality systems FDA_approval_for_hGH-CTP |
| gptkbp:research |
published in journals
|
| gptkbp:research_areas |
hormonal disorders
protein therapeutics |
| gptkbp:research_focus |
patient-centric approaches
|
| gptkbp:safety |
assessed in trials
|
| gptkbp:scientificName |
maintained in research practices
|
| gptkbp:sells |
gptkb:NASDAQ
|
| gptkbp:stakeholders |
prioritized in operations
|
| gptkbp:supportRole |
composed of industry experts
|
| gptkbp:targetMarket |
planned for hGH-CTP
|
| gptkbp:technology |
contributed to the field
|
| gptkbp:website |
www.prolorbiotech.com
|